breast cancer
Conditions
Interventions
Goserelin implant treatment group:NO
Goserelin microsphere treatment group:NO
Sponsors
First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Histopathologically confirmed breast cancer; 2. Age >=18 and <=55 years; 3. ECOG score 0~1; 4. Immunohistochemical determination of ER and (or) PR positivity; 5. Serum estradiol (E2) and follicle-stimulating hormone (FSH) levels at premenopausal levels before receiving goserelin treatment; 6. Serum estradiol (E2) and follicle-stimulating hormone (FSH) level testing at 8~28 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of psychiatric disorders, cognitive dysfunction, and major organic diseases; 2. Patients with concomitant other malignancies; 3. Patients with breast cancer metastasis, recurrence, or death during this period; 4. Patients with concomitant severe infections or severe underlying diseases such as liver, kidney, and cardiovascular and cerebrovascular diseases; 5. Patients with a history of severe allergy or intolerance to the drugs in this study; 6. Patients with severely incomplete medical records affecting the study results;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estradiol 2 (E2); | — |
Countries
China
Contacts
Public ContactGuo Yuanyuan
First Affiliated Hospital of Zhengzhou University
Outcome results
None listed